C-mo
Key Facts
| Invested since | 2022 |
| Based in | International |
About the company
C-mo Medical Solutions is an award-winning Digital Health start-up that develops solutions for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential of cough assessment and solve the major unmet medical needs associated with the management of chronic cough. The company was founded by Diogo Tecelão, Miguel Andrade, Filipe Valadas, Alexandra Lopes, Sara Lobo, and Nuno Neuparth, thus combining a wealth of knowledge on digital health, business development, and respiratory medicine.
Do you want to
know more about this company?
C-mo in the news
More startups from Life Sciences
CorTec is a young medical engineering company focusing on innovations in the field of neurotechnology. With CorTec Brain Interchange we are developing a direct interface between brain and technology.
To the complete profileof CorTec
Avelios Medical offers a modular software platform for the digitization of workflows in hospitals and data-driven patient care. The state-of-the-art software digitizes and optimizes all workflows in hospitals in a …
To the complete profileof Avelios Medical
Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator …
To the complete profileof Refoxy Pharma
neotiv is a spin-off of the Otto von Guericke University in the German city of Magdeburg in close collaboration with the Magdeburg site of the German Centre for Neurodegenerative Diseases …
To the complete profileof neotiv
Exit
PreOmics develops and provides innovative technologies for customers around the world for mass spectrometry (MS) – based proteomics using cutting-edge technologies to support researchers in their protein analysis needs.
To the complete profileof PreOmics
In order to successfully treat the infected patient, you have to recognize and diagnose most reliably the infecting microbe. Noscendo changes the way infection causative microbes are identified. Through a …
To the complete profileof Noscendo
Exit
KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare. Exit since Feb. 2011. Purchaser: Evotec AG
To the complete profileof KINAXO
Exit
LOEWI GmbH is a scientific spin-off of the TU München with the mission to make personalized health and nutrition available to everyone by combining science and technology. LOEWI’s patented personalization …
To the complete profileof LOEWI
Exit
MYR, acquired by Gilead Sciences in 2021, developed a peptide-based, first-in-class drug to combat chronic hepatitis B and delta. The drug has been approved by the EMA for the treatment …
To the complete profileof MYR
Exit
GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with …
To the complete profileof GQ Bio Therapeutics
hema.to is an easy-to-use software for clinical decision support for blood cancer from cytometry data using AI. hema.to makes the diagnostic workflow both faster and better, helping both diagnosticians as …
To the complete profileof hema.to
Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA …
To the complete profileof Pantherna Therapeutics